Enhanced Cellular Adenosine Uptake Limits Adenosine Receptor Stimulation in Patients With Hyperhomocysteinemia

Niels P. Riksen, Gerard A. Rongen, Godfried H.J. Boers, Henk J. Blom, Petra H.H. van den Broek, Paul Smits

Objective—Endogenous adenosine has several cardioprotective effects. We postulate that in patients with hyperhomocysteinemia increased intracellular formation of S-adenosylhomocysteine decreases free intracellular adenosine. Subsequently, facilitated diffusion of extracellular adenosine into cells through dipyridamole-sensitive transporters is enhanced, limiting adenosine receptor stimulation. We tested this hypothesis in patients with classical homocystinuria (n=9, plasma homocysteine 93.1±24.7 μmol/L) and matched controls (n=8, homocysteine 9.1±1.0).

Methods and Results—Infusion of adenosine (0.5, 1.5, 5.0, and 15.0 μg/min/dL forearm) into the brachial artery increased forearm blood flow, as measured with venous occlusion plethysmography, to 2.9±0.4, 4.3±0.5, 5.6±1.1, and 9.6±2.1 in the patients and to 2.8±0.6, 4.4±1.0, 9.0±1.7, and 17.0±3.1 mL/min/dL in controls (P<0.05). However, adenosine-induced vasodilation in the presence of dipyridamole (100 μg/min/dL) was similar in both groups (P=0.9). Additionally, in isolated erythrocytes, adenosine uptake was accelerated by incubation with homocysteine (half-time 6.4±0.3 versus 8.1±0.5 minutes, P<0.001) associated with increased intracellular formation of S-adenosylhomocysteine (P<0.0001).

Conclusions—In hyperhomocysteinemia, adenosine-induced vasodilation is impaired but is restored by dipyridamole. Accelerated cellular adenosine uptake probably accounts for these observations. These impaired actions of adenosine could well contribute to the cardiovascular complications of hyperhomocysteinemia. (Arterioscler Thromb Vasc Biol. 2005;25:109-114.)

Key Words: adenosine • hyperhomocysteinemia • dipyridamole • forearm • nucleoside transport

Hyperhomocysteinemia is an independent risk factor for atherosclerosis and thromboembolism. It is poorly understood which mechanism is responsible for these cardiovascular complications.

Recently, we and others have drawn attention to a new hypothesis, focusing on the influence of homocysteine on the metabolism of the endogenous nucleoside adenosine.1,2 According to this hypothesis, a homocysteine-induced fall in extracellular adenosine contributes to the cardiovascular sequelae of hyperhomocysteinemia. Fundamental to this is the reversibility of the reaction in which S-adenosylhomocysteine (AdoHcy) is hydrolyzed to form homocysteine and adenosine.3 Although the equilibrium constant of this reaction favors AdoHcy synthesis, under physiological conditions AdoHcy is hydrolyzed to homocysteine and adenosine, because both reaction products are rapidly metabolized. In hyperhomocysteinemia, the reaction shifts toward AdoHcy synthesis at the expense of free intracellular adenosine. Subsequently, facilitated diffusion of extracellular adenosine into the cells through the dipyridamole-sensitive equilibrative nucleoside transporter is enhanced, limiting stimulation of membrane-bound adenosine receptors (Figure 1).

By stimulation of these receptors, extracellular adenosine induces several effects, which could protect against the development of atherosclerosis and thrombosis and against ischemia-reperfusion injury.1,4 Particularly in situations of hypoxia or ischemia, when the concentration of adenosine increases rapidly, these effects work in concert to protect the affected tissue.5 Previous animal studies suggest that the effect of intracellular AdoHcy formation on the transmembranous adenosine gradient and thus diffusion of extracellular adenosine into the cells is most pronounced in these very situations of high concentrations of adenosine, thus limiting adenosine receptor stimulation when most needed.6,7 Therefore, we speculate that in hyperhomocysteinemia, decreased extracellular adenosine concentrations contribute to the development of the associated cardiovascular problems.
by guest on November 9, 2017 http://atvb.ahajournals.org/ Downloaded from

Vitamin B12 (10 μg), folic acid (5 mg, n = 9), betaine anhydricum (6 g, n = 100), and cholesterol were added to patients who were considered eligible, and nine agreed to participate and receive treatment (right). Dipyridamole inhibits cellular adenosine uptake by blockade of the ENT. AMP indicates adenosine mono-phosphate; 5'-NT, 5'-nucleotidase; ADA, adenosine deaminase; AK, adenosine kinase; Ino, inosine; Met, methionine; ENT, equilibrative nucleoside transporter. In the present study, we addressed this issue in patients with severe hyperhomocysteinemia. We estimated basal intravascular and muscle interstitial adenosine concentration by microdialysis. Secondly, we measured adenosine-induced forearm vasodilation. According to our hypothesis, accelerated cellular adenosine uptake would decrease the amount of free extracellular adenosine able to stimulate adenosine receptors and, consequently, would attenuate adenosine-induced vasodilation in this patient group. Inhibition of cellular adenosine uptake by dipyridamole should restore this diminished response. Additionally, we aimed to more directly demonstrate homocysteine-induced increased intracellular formation of AdoHcy and subsequent accelerated adenosine uptake in isolated human erythrocytes.

Methods

Subjects

After approval of the local ethics committee, adult patients with hyperhomocysteinemia due to homozygous cystathionine β-synthase deficiency from our outpatient clinic were asked to participate if their fasting total plasma homocysteine was more than 20 μmol/L despite treatment. Exclusion criteria were mental retardation, previous vascular events, asthma, and oral anticoagulation. Twelve patients were considered eligible, and nine agreed to participate and signed informed consent. Their homocysteine-lowering therapy consisted of vitamin B6 (250 to 750 mg, n = 9), folic acid (5 mg, n = 9), vitamin B12 (10 μg orally each day or 1 mg intramuscularly each two months, n = 7), and betaine anhydricum (6 g, n = 7). Further treatment consisted only of acetylsalicylic acid (80 mg in one patient; stopped one week before the experiment) and adренон (70 mg weekly in 2 patients). A control group of eight healthy volunteers was composed with similar age and body mass index as the patient group.

Instrumentation

All tests were performed in the morning in a temperature-controlled laboratory (23°C) after an overnight fast and 24 hours of caffeine abstinence.

After local anesthesia (xylocaine 2%), a microdialysis probe (CMA/70 microdialysis catheter, Microdialysis AB) was inserted into the flexor digitorum superficialis muscle of the nondominant arm, guided by a 14-gauge venflon cannula. An identical microdialysis probe was inserted into a deep antebracial vein of the same arm. Each probe was connected to a microdialysis pump (CMA/107 microdialysis pump, Microdialysis AB) and continuously perfused with isotonic saline at 2 μL/min. The effluent was collected at 15-minute intervals to obtain 30-μL samples (dialysate). Samples were stored at −20°C until analysis.

Subsequently, the brachial artery of the nondominant arm was cannulated and forearm blood flow (FBF) was measured in each arm using mercury-in-silastic venous occlusion plethysmography as described previously. Each drug dosage was infused for 5 minutes.

In the first hour of the study, blood was drawn for determination of plasma total homocysteine, AdoHcy, S-adenosylmethionine (AdoMet), vitamin B6, folate, vitamin B12, and cholesterol.

Experimental Protocol

Immediately after insertion of the microdialysis probes, dialysate sampling was started. Two hours after insertion, both microdialysis probes were removed and suspended in isotonic saline for in vitro calibration, as previously described.

Subsequently, baseline FBF was measured during infusion of saline followed by infusion of increasing dosages of adenosine (0.5, 1.5, and 15 μg/min/dL forearm). After 30 minutes of equilibration, baseline FBF measurement was repeated, followed by infusion of dipyridamole (100 μg/min/dL) and increasing dosages of adenosine (0.15, 0.5, and 1.5 μg/min/dL) on top of dipyridamole infusion. In combination with dipyridamole, we used lower concentrations of adenosine because of the well-known potentiating effect of dipyridamole on adenosine-induced vasodilation. Finally, maximal vasodilation was measured during postocclusive reactive hyperemia to test for possible structural vascular changes in the patient group, as described previously.

Adenosine Uptake in Isolated Erythrocytes

In 6 additional healthy volunteers, erythrocytes were isolated for in vitro experiments. In hyperhomocysteinemia, erythrocytes are relevant to our hypothesis. Under normal conditions, adenosine is efficiently taken up by erythrocytes through the dipyridamole-sensitive transporter and because homocysteine and AdoHcy are transported in the ENT. AMP indicates adenosine mono-phosphate; 5'-NT, 5'-nucleotidase; ADA, adenosine deaminase; AK, adenosine kinase; Ino, inosine; Met, methionine; ENT, equilibrative nucleoside transporter.

Drugs and Solutions

Solutions of adenosine (Adenocor, Sanofi-Synthelabo) and dipyridamole (Persantin, Boehringer Ingelheim) were freshly prepared with NaCl 0.9% as solvent. L-homocysteine was freshly prepared immediately before each in vitro experiment from 1.0-mol/L L-homocysteine thiolactone as previously described.

Analytical Procedures

Dialysate adenosine concentration was determined by high-performance liquid chromatography (HPLC) with reversed-phase ion-pairing separation and UV detection. Plasma homocysteine was determined by reverse phase (RP)-HPLC as described previously.

Plasma AdoHcy and AdoMet were determined by tandem mass spectrometry, based on the work of Struyf et al.
TABLE 1. Demographic Characteristics of the Study Groups

<table>
<thead>
<tr>
<th></th>
<th>Patients</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>No.</td>
<td>9</td>
<td>8</td>
</tr>
<tr>
<td>Sex (male/female)</td>
<td>8/1</td>
<td>6/2</td>
</tr>
<tr>
<td>Age (years)</td>
<td>36.3±2.2</td>
<td>36.8±4.9</td>
</tr>
<tr>
<td>Body mass index (kg/m^2)</td>
<td>25.4</td>
<td>24.4±1.5</td>
</tr>
<tr>
<td>Smoking (No.)</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Systolic blood pressure (mm Hg)*</td>
<td>126±4</td>
<td>116±3</td>
</tr>
<tr>
<td>Diastolic blood pressure (mm Hg)*</td>
<td>72±4</td>
<td>67±3</td>
</tr>
<tr>
<td>Heart rate (bpm)†</td>
<td>64±4</td>
<td>57±2</td>
</tr>
<tr>
<td>Glucose (mmol/L)</td>
<td>4.9</td>
<td>5.2±0.3</td>
</tr>
<tr>
<td>Cholesterol (mmol/L)</td>
<td>4.9</td>
<td>4.6±0.3</td>
</tr>
<tr>
<td>Total homocysteine (μmol/L)</td>
<td>93.1±24.7</td>
<td>9.1±1.0</td>
</tr>
<tr>
<td>S-adenosylhomocysteine (nmol/L)</td>
<td>41.8±10.0</td>
<td>7.7±0.8</td>
</tr>
<tr>
<td>Vitamin B12 (pmol/L)</td>
<td>258±18</td>
<td>284±30</td>
</tr>
<tr>
<td>Vitamin B6 (nmol/L)</td>
<td>4315±305</td>
<td>75±5</td>
</tr>
<tr>
<td>Folate (nmol/L)§</td>
<td>155±39</td>
<td>12±1</td>
</tr>
</tbody>
</table>

*Intra-arterially and †electrocardiographically measured during saline infusion.
‡P<0.005 compared to control group.
§Upper limit of detection 270 nmol/L.

Statistics
Values are expressed as mean±SE unless otherwise stated. P<0.05 is considered statistically significant. Because plasma concentrations of homocysteine, AdoHcy, AdoMet, and vitamins did not show a Gaussian distribution (P>0.1; Shapiro–Wilk test for normality), the Mann–Whitney test was used to compare groups. Other baseline parameters were normally distributed, and consequently a Student t test was used.

To compare adenosine-induced vasodilation between the two groups, a repeated measures ANOVA was used. Finally, for each subject, the area under the curves (AUC) of change in FBF was calculated for the adenosine-induced vasodilation with and without dipyridamole. The ratio of the AUC (with dipyridamole) and the AUC (without dipyridamole) was used to quantify the effect of dipyridamole. Because these ratios were not normally distributed, a Mann–Whitney test was used to compare groups.

In the in vitro experiments, the decrease of extracellular adenosine in time was fitted according to one phase exponential decay (GraphPad Prism version 4.00 for Windows, GraphPad Software), and half times were compared with paired Student t test.

Results
Baseline Characteristics
Demographic data are shown in Table 1. Plasma concentrations of total homocysteine, AdoHcy, and AdoMet were higher in the patient group (P<0.005). Treatment with high-dose folic acid and pyridoxine resulted in higher plasma concentrations of folate and vitamin B6 in the patient group (P<0.005). In one patient, we were not able to insert the intramuscular and intravascular probes, and consequently only data on interstitial adenosine were available.

Microdialysis Experiments
Immediately after intramuscular insertion, dialysate adenosine concentration is known to be high because of myocyte damage and decreases to baseline level within one hour. To estimate basal interstitial adenosine concentration, we averaged the dialysate concentration of the two consecutive dialysate samples taken 1.5 hours after insertion. In the patient group, basal adenosine concentration was 96±21 nmol/L (n=7; 2 patients were excluded because of extremely low concentration of creatine and phosphocreatine in the first microdialysis sample, indicating misplacement of the probe), whereas in the control group basal adenosine concentration was 73±9 nmol/L (n=8, P=0.3).

The dialysate adenosine concentration from the intravascular probe was at steady-state immediately after insertion. Therefore, we averaged the values of all dialysate samples to one value. In the patient group this baseline concentration yielded 142±33 nmol/L (n=8), whereas in the control group it yielded 135±25 nmol/L (n=8, P=0.7). Adenosine recovery of the intramuscular and intravascular probes was 48±4% and 47±5% for patients and 47±4% and 39±2% for controls, respectively (P=0.9 and 0.2, respectively).

Plethysmography Experiments
Baseline FBF in the infused arm was 2.0±0.2 and 2.5±0.5 mL/min/dL for patients and controls, respectively (n=8; P=0.4). During infusion of increasing adenosine doses, FBF in the patient group was 2.9±0.4, 4.3±0.5, 3.6±1.1, and 9.6±2.1 mL/min/dL, respectively (Figure 2). In the control group, FBF was 2.8±0.6, 4.4±1.0, 9.0±1.7, and 17.0±3.1 mL/min/dL, respectively. This adenosine-induced vasodilation was attenuated in the patient group (P<0.05).

After 30-minute equilibration, baseline FBF was 2.7±0.3 and 3.1±0.7 mL/min/dL in the patient group and control group, respectively (n=8; P=0.6). Infusion of dipyridamole increased FBF to 4.3±0.5 mL/min/dL in patients and to 4.7±1.0 in controls (P=0.7 between groups). Subsequent infusion of adenosine on top dipyridamole increased FBF to 10.9±1.6, 16.3±2.6, and 27.2±2.9 mL/min/dL in patients and to 8.8±1.4, 14.8±2.4, and 24.4±4.0 in controls, respectively (P=0.9). The ratio of the AUC for adenosine-induced vasodilation with dipyridamole and without dipyridamole was 0.40±0.08 in the patient group and 0.16±0.03 in the control group (P<0.05). Moreover, with both experimental groups taken together, there was a negative correlation between total plasma homocysteine concentration and the

Figure 2. Adenosine-induced vasodilation without dipyridamole (squares) and during coinfusion with dipyridamole (triangles) in patients (open symbols; mean±SE, n=8) and controls (filled symbols; n=8).
**TABLE 2. Systemic Effects of Adenosine Infusion**

<table>
<thead>
<tr>
<th>Heart Rate</th>
<th>Mean Arterial Pressure</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Patients</td>
</tr>
<tr>
<td>Baseline 1</td>
<td>62±4</td>
</tr>
<tr>
<td>Ado 0.5</td>
<td>61±4</td>
</tr>
<tr>
<td>Ado 1.5</td>
<td>63±4</td>
</tr>
<tr>
<td>Ado 5.0</td>
<td>62±4</td>
</tr>
<tr>
<td>Ado 15.0</td>
<td>65±3*</td>
</tr>
<tr>
<td>Baseline 2</td>
<td>64±4</td>
</tr>
<tr>
<td>Dipy</td>
<td>66±5</td>
</tr>
<tr>
<td>Dipy+ado 0.15</td>
<td>69±4</td>
</tr>
<tr>
<td>Dipy+ado 0.5</td>
<td>70±4</td>
</tr>
<tr>
<td>Dipy+ado 1.5</td>
<td>76±5†</td>
</tr>
</tbody>
</table>

*Significant increase in heart rate as compared to baseline 1 (P<0.05) and †baseline 2 (P<0.001). No differences between groups.

Adenosine Uptake in Isolated Erythrocytes

Plasma homocysteine of the 6 subjects in this study averaged 9.1±0.9 μmol/L. Adenosine uptake into the erythrocytes and subsequent metabolism results in a decrease of extracellular adenosine in time (Figure 3a). Adenosine uptake was accelerated by incubation with homocysteine (half time 6.4±0.3 versus 8.1±0.5 minutes, P<0.001). Intracellularly, AdoHcy increased in time in cells incubated with homocysteine, but not in control samples (Figure 3b; P<0.0001, ANOVA for repeated measures). At 6 minutes, adenosine in the supernatant was lower in the homocysteine-incubated cells. This absolute homocysteine-induced difference in adenosine concentration significantly increased when the initial adenosine concentration was varied from 0.125 μmol/L to 2.0 μmol/L (Figure 3c and 3d; P<0.05, ANOVA for repeated measures).

Finally, dipyridamole significantly inhibited the accelerating effect of homocysteine on cellular adenosine uptake. Homocysteine decreased the free extracellular adenosine concentration after 6 minutes of adenosine uptake with 14.5±0.5% in the absence and with 2.9±0.5% in the presence of dipyridamole (Figure 4; P<0.05, n=2).

**Discussion**

In the present study, we show for the first time that adenosine-induced forearm vasodilation is attenuated in patients with hyperhomocysteinemia due to classical homocystinuria, and that this attenuation is completely restored by coinfusion of the adenosine uptake inhibitor dipyridamole.

The association between hyperhomocysteinemia and atherosclerosis and thrombosis was first established in patients with classical homocystinuria. 

Without treatment, 50% of suchlike patients experience a vascular event before the age of 30 years. Treatment is aimed at minimizing the biochemical abnormalities and consists of pyridoxine (vitamin B6) and folic acid and, if necessary, betaine anhydricum and vitamin B12. This treatment regimen significantly improves vascular outcome. Our patients continued to have elevated plasma homocysteine levels despite treatment. Because of the defective degradation of homocysteine to cystathionine, homocysteine can only be remethylated to methionine or converted to AdoHcy. This altered metabolic profile is illustrated by the increased plasma concentrations of AdoHcy and concentration after 6 minutes of adenosine uptake.
AdoMet in our patient group. Previous in vivo experiments on vascular function in this patient group are scarce and demonstrated impaired flow-mediated dilation and carotid artery wall hypertrophy.21–23

In the present study, adenosine-induced forearm vasodilation was reduced in patients with hyperhomocysteinemia. Based on the observations that dipyridamole restores this impaired vasodilation and that in erythrocytes homocysteine accelerates cellular adenosine uptake, we conclude that this impaired adenosine-induced vasodilation is caused by accelerated cellular adenosine uptake. Adenosine-induced vasodilation is partly endothelium-dependent.24 We did not use alternative endothelium-dependent vasodilators to test for endothelial function in our patient group. However, as shown by previous studies in patients with classical homocystinuria, endothelial dysfunction could well also be present in our patients. Could endothelial dysfunction or structural vascular damage, both previously described in a comparable patient group, challenge our conclusion? In our opinion this is not the case. The observation that dipyridamole restored adenosine-induced vasodilation suggests that accelerated adenosine uptake through the equilibrative nucleoside transporter, rather than endothelial dysfunction, accounts for the attenuated vasodilation. It needs to be realized that dipyridamole is proposed to have alternative mechanisms of actions besides inhibition of endothelium-dependent vasodilation, thus improving this portion of adenosine-induced vasodilation. However, in an identical experimental model as in the present study, our group has previously shown that dipyridamole-induced local vascular effects are indeed solely caused by adenosine uptake inhibition. Dipyridamole potentiated the vasodilator response to adenosine,10 and dipyridamole-induced vasodilation (100 \( \mu \)g/min/dL) was inhibited by the adenosine receptor antagonist theophylline.26 Moreover, we showed in isolated erythrocytes that homocysteine indeed accelerates cellular adenosine uptake, which is counteracted by dipyridamole. Although the effects of homocysteine in this model are rather modest, these in vitro observations provide additional evidence that accelerated cellular adenosine uptake might account for the observed impaired adenosine-induced vasodilation.

Minimal forearm vascular resistance was similar in both groups. This parameter accurately reflects structural arteriolar status,27 indicating that in our patient group, at least in the forearm vascular bed, no structural vascular changes were present. It should be mentioned that reactive hyperemia is shown to be partially adenosine-dependent.28 This portion of the hyperemia in our study would theoretically be diminished in the patients with hyperhomocysteinemia. However, because of the maximal stimulus for vasodilation after 13 minutes of ischemia, other mediators probably compensate for this decrease in adenosine-induced vasodilation.27

In previous experiments, it was shown in guinea pig hearts29–30 and rat brain31 that perfusion with homocysteine (thiolactone) decreased organ release of adenosine. The results from our in vitro experiments showed that also in human erythrocytes, homocysteine accelerates cellular uptake of adenosine. Moreover, we demonstrated that this is indeed associated with increased intracellular formation of AdoHcy. Finally, this effect of homocysteine is more pronounced at higher concentration of adenosine (Figures 2 and 3). This observation could well explain why baseline endogenous adenosine, as estimated by microdialysis, was not reduced in our patient group. This is in strong contrast to the study by Chen et al, which demonstrated an \( \approx 50\% \) reduction in endogenous baseline adenosine concentration induced by mild elevation of plasma homocysteine from 6.7 ± 0.4 to 14.7 ± 0.5 \( \mu \)mol/L.2 This discrepancy could be caused by the differences between man and rat concerning protein-binding characteristics of the equilibrative nucleoside transporter.32 Also, the experimental methionine-induced hyperhomocysteinemia in the rat model differs from the hyperhomocysteinemia in our patient group, possibly affecting tissue and cellular distribution of homocysteine. But most importantly, the results from our in vitro studies suggest that the effect of AdoHcy synthesis on the rate of cellular adenosine uptake is limited to situations of high extracellular adenosine concentrations, as for example in ischemia, when myocardial interstitial adenosine concentration can increase up to 40-fold in pigs.7 A recent microdialysis study on the pig heart showed that local application of homocysteine reduced dialysate adenosine concentration during hypoxia, but not during normoxia.7 Likewise, Kloor et al concluded from a rat study that homocysteine is the rate-limiting factor for AdoHcy synthesis in hypoxic conditions when tissue levels of adenosine are elevated, whereas in normoxia the availability of free adenosine is rate-limiting.6 This suggests that also in vivo, the effect of homocysteine on adenosine concentration is more pronounced and therefore more easily detected in situations of high concentrations of adenosine than under normoxic baseline conditions. Unfortunately, for practical reasons we were not able to collect microdialysis samples during infusion of adenosine or during ischemia.

We have shown that the vasodilating effect of adenosine, which was reduced in hyperhomocysteinemia, was com-
pletely restored by the nucleoside uptake inhibitor diprydami-
ole. Extrapolating this finding, diprydiamole would be bene-
ficial in patients with hyperhomocysteinemia by preserving
the protective cardiovascular effects of adenosine in hypoxia
or ischemia. To our best knowledge, diprydiamole has never
been tested systematically in such patients in clinical trials.

Several limitations of the present study need to be dis-
cussed. First, we used a group of patients with classical
homocystinuria, using high doses of vitamins, including
vitamin B6 and folic acid. It remains to be established
whether changes in adenosine metabolism are also important
in patients with mild hyperhomocysteinemia. Considering the
vitamin therapy in our patient group, we are not aware of any
actions of these vitamins on nucleoside transport. Secondly,
considering the large interindividual variation, microdialysis
may lack sufficient sensitivity to exclude subtle differences in
baseline adenosine concentration between the two study
groups. Moreover, the values obtained with microdialysis
might not reflect the adenosine concentrations in specific
microenvironments, such as near the endothelial lining.

In conclusion, in patients with severe hyperhomocysteine-
 mia, adenosine-induced effects are impaired, which could
contribute to the cardiovascular complications of this disease.

Acknowledgments

N.P.R. is a MD–clinical research trainee financially supported by the
Netherlands Organization for Scientific Research (ZonMw). G.A.R.
is a fellow of the Royal Netherlands Academy of Arts and Sciences.
H.J.B. is an established investigator of the Netherlands Heart
Foundation (D97.021). The contribution of P.H.H.v.d.B. was finan-
cial in patients with hyperhomocysteinemia by preserving
the protective cardiovascular effects of adenosine in hypoxia
or ischemia. To our best knowledge, diprydiamole has never

References

1. Riksen NP, Rongen GA, Blom HJ, Russel FGM, Boers GH, Smits P. Poten-
tial role for adenosine in the pathogenesis of the vascular complica-
2. Chen YF, Li PL, Zou AP. Effect of hyperhomocysteinemia on plasma or
  tissue adenosine levels and renal function. Circulation. 2002;106:
  1275–1281.
3. Ueland PM. Pharmacological and biochemical aspects of
  S-adenosylhomocysteine and S-adenosylhomocysteine hydrolase.
4. Rongen GA, Floras JS, Lenders JW, Thien T, Smits P. Cardiovascular
5. Ely SW, Berne RM. Protective effects of adenosine in myocardial ische-
6. Klooi D, Delabar U, Muhlauer B, Luipoldt G, Osswald H. Tissue levels of
  S-adenosylhomocysteine in the rat kidney: effects of ischemia and
7. Lasley RD, Hegge JO, Noble MA, Mentzer RM. Evidence that cytosolic
  and ecto S'-nucleotidases contribute equally to increased interstitial aden-
  osine concentration during porcine myocardial ischemia. Basic Res
8. Rongen GA, Ginneken E, Thien T, Lutterman JA, Smits P. Preserved
  vasodilator response to adenosine in insulin-dependent diabetes mellitus.
  skeletal muscle interstitial adenosine during forearm dynamic exercise in
10. van Ginneken EE, Rongen GA, Russel FG, Smits P. Diadenosine penta-
  phosphosphate vasodilates the forearm vascular bed: inhibition by theoph-
11. Plagemann PG, Wohlueter RM, Kraupp M. Adenosine uptake, transport,
  and metabolism in human erythrocytes. J Cell Physiol. 1985;125:
12. Jarvis SM. Nitrobenzylthionosine-sensitive nucleotide transport system:
  mechanism of inhibition by diprydiamole. Mol Pharmacol. 1986;30:
  659–665.
13. Pema AF, Ingrosso D, De Santo NG, Galletti P, Zappia V. Mechanism of
  erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine
14. Manoon MA, Guttermann AB, Fiskerstrand T, Rensum H, Ueland PM,
  Svardal AM, Redox status and protein binding of plasma aminothiol
  during the transient hyperhomocysteinemia that follows homocysteine
15. te Poele-Pothoff MT, van den Berg M, Franken DG, Boers GH, Jacobs B,
  de Koon IF, Eskes TK, Tijbels JM, Blom HJ. Three different methods
16. Struys EA, Jansen EE, de Meer K, Jacobs B. Determination of S-
  adenosylmethionine and S-adenosylhomocysteine in plasma and cere-
  brospinal fluid by stable-isotope dilution tandem mass spectrometry. Clin
17. McCulley KS. Vascular pathology of homocystinuria: implications for
18. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE,
  Andria G, Boers GH, Bromberg IL, Cerone R. The natural history of
  homocystinuria due to cystathionine beta-syntha-ase deficiency. Am J Hum
  CR, Beaudet AL, Sly WS, Vale D, eds. The Metabolic and Molecular
  Naughten ER. Vascular outcome in patients with homo-
  cystinuria due to cystathionine beta-syntha-ase deficiency treated chron-
  JV, Deanfield JE. Impaired endothelial function occurs in the systemic
  arteries of children with homozgyous homocystinuria but not in their
22. Pullin CH, Bonham JR, McDowell IF, Lee PJ, Powers HJ, Wilson JF,
  Lewis MJ, Moat SJ. Vitamin C therapy ameliorates vascular endothelial
  dysfunction in treated patients with homocystinemia. J Inherit Metab Dis.
23. Megnien JL, Garijpy J, Saudubray JM, Nourof JM, Denarie N, Levenson
  J, Simon A. Evidence of carotid artery wall hypertrophy in homozygous
  Endothelial release of nitric oxide contributes to the vasodilator effect of
  Glyburide inhibits diprydiamole-induced forearm vasodilation but not adeno-
  sine-induced forearm vasodilation. Clin Pharmacol Ther. 2004;75:
  147–156.
27. Pedrinielli R, Spessot M, Salvetti A. Reactive hyperemia during short-
  term blood flow and pressure changes in the hypertensive forearm. J
  Hypertens. 1990;8:467–471.
28. Carlsson I, Sollevi A, Wennmalm A. The role of myogenic relaxation,
  adenosine and prostaglandins in human forearm reactive hyperaemia.
29. Schrader J, Schutz W, Bardenheuer H. Role of S-adenosylhomocysteine
  hydrolase in adenosine metabolism in mammalian heart. Biochem J.
30. Deussen A, Brorst M, Schrader J. Formation of S-adenosylhomocysteine
  in the heart. I: An index of free intracellular adenosine. Eur J Cell
31. Sciott VM, Van Wylen DG. Attenuation of ischemia-induced extra-
  cellular adenosine accumulation by homocysteine. J Cereb Blood Flow
32. Griffith DA, Jarvis SM. Nucleoside and nucleobase transport systems of
Enhanced Cellular Adenosine Uptake Limits Adenosine Receptor Stimulation in Patients With Hyperhomocysteinemia

Niels P. Riksen, Gerard A. Rongen, Godfried H.J. Boers, Henk J. Blom, Petra H.H. van den Broek and Paul Smits

_Arterioscler Thromb Vasc Biol._ 2005;25:109-114; originally published online November 11, 2004;
doi: 10.1161/01.ATV.0000150651.85907.69

_Arteriosclerosis, Thrombosis, and Vascular Biology_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2004 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://atvb.ahajournals.org/content/25/1/109

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Arteriosclerosis, Thrombosis, and Vascular Biology_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Arteriosclerosis, Thrombosis, and Vascular Biology_ is online at:
http://atvb.ahajournals.org//subscriptions/